Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
Year: 2020
Type: article
Study design: Clinical Trial
Abstract: One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (Alliance), a 2 × 2 factorial, open-label, randomized phase II trial, evaluated the impact of adding carboplatin and/or bevacizumab.
DOI: 10.17615/t7c3-h016
Authors: Cirrincione, Constance T., Collyar, Deborah, Hudis, Clifford A., Pluard, Timothy J., Carey, Lisa A., Kuzma, Charles S., Golshan, Mehra, Somlo, George, Bellon, Jennifer R., Port, Elisa R., Perou, Charles M., Tolaney, Sara M., Winer, Eric P., Hahn, Olwen M., Berry, Donald A., Sikov, William M., Singh, Baljit
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W4299816404